Alumis Inc.
ALMS
Rang in Aktien
#9912
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the... Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.
Aktienkurs
$6.78
Marktkapitalisierung
$877.57M
Veränderung (1 Tag)
1.19%
Veränderung (1 Jahr)
198.68%
Land
US
Handel Alumis Inc. (ALMS)
Kategorie
Healthcare
Kursverlauf für Alumis Inc. (ALMS)
Höchster Schlusskurs: $2.34 am 2025-05-01
Niedrigster Schlusskurs: $21.58 am 2023-05-01
Niedrigster Schlusskurs: $21.58 am 2023-05-01
Kursverlauf der Aktie von Alumis Inc. von 2023 bis 2026
Jährliche Kursentwicklung
| Jahr | Leistung |
|---|---|
| 2025 | -35.06% |
| 2024 | -49.49% |
| 2023 | 0.00% |
Aktienkurs vergleichbarer Unternehmen oder Wettbewerber
| Unternehmen | Aktienkurs | Veränderung 1J% | Land |
|---|---|---|---|
| $527.18 | 23.67% |
US
|
|
| $251.29 | 814.11% |
US
|
|
| $138.33 | -3.31% |
AU
|
|
| $890.85 | 6.72% |
NL
|
|
| $752.87 | 7.40% |
CH
|
